- Design
- population pharmacokinetic modelling with post hoc Bayesian estimation and dosing simulation
- Population
- 15 patients contributing 83 tacrolimus concentrations before and after nirmatrelvir/ritonavir, Japanese national university hospitals
- Primary outcome
- change in tacrolimus clearance and relative bioavailability, and simulated optimal restart schedule
- Effect
- clearance almost completely inhibited; relative bioavailability increased 7.99-fold
Nirmatrelvir/ritonavir inhibits CYP3A and P-glycoprotein, and the effect on tacrolimus is not a modest interaction. Pooling 83 tacrolimus concentrations from 15 patients at Japanese national university hospitals, before and after co-administration, the analysis estimated that tacrolimus clearance was almost completely inhibited and relative bioavailability rose 7.99-fold.
The package insert covers the start - withhold or reduce the tacrolimus - and says little about the restart, which is where the practical difficulty sits. Ritonavir's inhibition does not stop when the course does; CYP3A activity recovers over days as enzyme is resynthesised, so a full dose resumed too early meets a liver that is still partly inhibited. The simulated schedule withholds tacrolimus during the antiviral course, then restarts at 10% of the baseline dose on day 1 after it stops, 20% on day 3, 50% on day 6 and 100% on day 9.
This is a model built on 15 patients, not a trial, and it is a proposal rather than a validated protocol. The number worth carrying regardless is that the recovery is measured in days, not hours. Nirmatrelvir/ritonavir is widely available in India and is prescribed by clinicians who may not be the ones managing the transplant. A transplant recipient starting it needs the immunosuppression plan made at the same time, and trough monitoring on restart is the safeguard the model does not replace.
- Withhold tacrolimus during nirmatrelvir/ritonavir rather than reducing the dose.
- Restart low and climb over about nine days - enzyme inhibition outlasts the course.
- Measure a trough before each step up; the schedule is a starting point, not a substitute for monitoring.
- Make the immunosuppression plan when the antiviral is prescribed, not when the patient calls.
- The same principle applies to ciclosporin, sirolimus and everolimus, which share CYP3A dependence.
Why it matters
The restart is the part no label addresses, and it is where a transplant recipient meets either rejection or toxicity.
Don't overread it
A simulation from 15 patients - the schedule is a proposal to monitor against, not a validated protocol.
The statistics, in plain English
An eightfold rise in relative bioavailability with near-total clearance inhibition is a very large interaction, and the direction is not in doubt. But the schedule comes from simulation on a model fitted to 15 patients, so the specific percentages carry much more uncertainty than the principle. Between-patient variability in CYP3A recovery is exactly what a 15-patient model cannot characterise, which is why the trough level rather than the table is what should govern each step.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free